This study looks at the safety and benefits of combining different treatments for melanoma that has spread to the brain, also known as brain metastases. Melanoma is a type of skin cancer. The treatments include:

• Stereotactic radiosurgery (SRS): A precise type of radiation therapy used to target brain tumors.
• Immune checkpoint inhibitors (ICI): Medications like pembrolizumab, nivolumab, and ipilimumab that help your immune system fight cancer.
• NovoTTF-100M: A device worn on the skin that uses electric fields to stop cancer cells from dividing.

Participants will either receive pembrolizumab or a combination of nivolumab and ipilimumab, along with SRS and NovoTTF-100M daily for 8 hours until their cancer progresses or side effects become unacceptable. The study lasts for 28 days after treatment. To join, patients must be 22 or older, have melanoma, and be able to follow the study requirements.

Key Points:

• The treatment involves wearing a device for 8 hours a day.
• Participants are monitored for side effects and cancer progression.
• The study includes a follow-up period after treatment ends.